Pfizer Recalls Levoxyl Tablets Due to Subpotent Drug Levels
Pfizer is recalling 15,815 bottles of Levoxyl (levothyroxine sodium) 175 mcg tablets because stability testing confirmed the drug was subpotent.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the source identifies the hazard as a subpotent drug confirmed by out-of-specification assay during stability testing. The source does not report any illnesses, injuries, or deaths.
Plain-English summary
Pfizer is recalling 15,815 bottles of Levoxyl (levothyroxine sodium) 175 mcg tablets. The recall was initiated because stability testing confirmed that the drug was subpotent, meaning it contained less of the active ingredient than specified.
The affected product is identified by Lot # 24W06 with an expiration date of 11/30/2026. The product was distributed nationwide in the United States and in Puerto Rico.
Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for guidance on obtaining a replacement or alternative treatment.
The recalled product
- Product
- LEVOXYL (LEVOTHYROXINE SODIUM)
- Brand
- LEVOXYL
- Manufacturer
- Pfizer
- Category
- Drug — Prescription Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 24W06
- Exp: 11/30/2026
UPCs (11)
- 0360793856018
- 0360793850016
- 0360793852010
- 0360793851013
- 0360793857015
- 0360793853017
- 0360793854014
- 0360793858012
- 0360793855011
- 0360793859019
- 0360793860015
Distribution
Related recalls
Same brand · LEVOXYL
- SeverePfizer Recalls Subpotent Levoxyl Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-10-28
- HighLevoxyl 50 microgram levothyroxine tablets recalled as a subpotent drug
FDA (Drugs) · 2025-08-20
- ModerateCardinal Health Recalls LEVOXYL Tablets Due to Temperature Excursions
FDA (Drugs) · 2021-06-02
- SeverePfizer Recalls Levoxyl Levothyroxine Sodium Tablets Due to Superpotency
FDA (Drugs) · 2018-12-26
- SeverePfizer Recalls LEVOXYL Levothyroxine Sodium Tablets Due to Superpotency
FDA (Drugs) · 2016-11-30
Same manufacturer · Pfizer
See all →- SeverePfizer Recalls Dopamine Hydrochloride Injection Due to Sterility Concerns
FDA (Drugs) · 2026-09-23
- SevereDrug recall: Bleomycin injection vials recalled due to glass contamination
FDA (Drugs) · 2024-01-31
- SeverePfizer Recalls Daptomycin Injection Due to Microbial Contamination
FDA (Drugs) · 2018-08-08
- HighPfizer Recalls PureSilk Shave Gel for Women Due to Rupture Risk
CPSC · 1996-07-02
Same hazard · subpotent drug
See all →- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02